Synvect is a biotechnology company focused on combating mosquito-borne diseases through innovative biological solutions. Their primary technology leverages CRISPR gene editing to create sterilized male mosquitoes that can effectively suppress wild mosquito populations. By inducing gene knockouts in mosquito eggs, Synvect produces non-biting males that, when released into the environment, mate with wild females, leading to a decline in the overall mosquito population. This method is not only cost-efficient and scalable but also user-friendly, allowing for easy deployment without the need for professional assistance. The company’s flagship product, the next-generation Sterile Insect Technique (ngSIT), utilizes a suppression box that contains these sterilized eggs, which hatch and emerge as males ready to mate.

In addition to ngSIT, Synvect offers a product called SEPARATOR, which enhances the efficiency of mosquito production by enabling high-throughput sex-sorting of male larvae using fluorescent markers. This technology allows for the early identification and separation of male larvae, significantly increasing the yield of male mosquitoes while reducing the resources spent on rearing females. Both technologies are designed to be environmentally safe, targeting only specific mosquito species, such as Aedes aegypti, which are known carriers of diseases like dengue and Zika. By focusing on precision-guided genetic modifications, Synvect aims to provide a sustainable and effective solution to the growing problem of mosquito-borne diseases.

United States

A biotechnology platform to develop safe, scalable, and effective solutions to eliminate disease-transmitting vectors, starting with the world's deadliest animal: the mosquito.

Synvect

Company Details